ISPO

HER-2/neu drug development

Herstatin, an alternative HER-2/neu product, suppresses receptor activity and growth of cells that overexpress p185HER-2 or the EGF receptor

JK Doherty MD PhD , MD Denton BA , N Azios BA , B Lin MS , GM Clinton PhD

Phage display selection of peptides reacting with ErbB-2 receptor and synthesis of peptabody molecules which bind specifically to ErbB-2^(+) cancer cells

M Houimel PhD , P Schneider PhD , A Terskikh PhD , J Mach MD

p27Kip1 is haplo-insufficient for suppression of Neu-induced mammary tumor growth in transgenic mice

J Hulit MS , RJ Lee PhD , B Bouzahzah PhD , R Francis , JN Zhou PhD , CW Wang PhD , R Russell PhD , RG Pestell MD PhD

Her-2/neu oncogene amplification in clinically localized prostate cancer

JD Oxley MB BS , M Winkler MB BS , D Gillatt MB ChB , DS Peat PhD

Immunohistochemical evaluation of K-ras, p53, and Her-2/neu expression in pancreatic lesions: evidence for multistep carcinogenesis

SK Apple MD, JR Hecht MD, DN Lewin MD, SA Jahromi BS, WW Grody MD PhD, RK Nieberg MD

RT-PCR detection of circulating breast cancer cells: Sensitivity and specificity of HER2/neu as a marker

LM Wasserman MD , V Jones MD , D Easter MD , A Wallace MD